Second quarter (2023-12-01 until 2024-02-29)
● Operating Income amounted to 2,405 (2,734) TSEK, of which
Cellaviva amounted to 2,334 (2,107) TSEK.
● Net Income amounted to 2,334 (2,106) TSEK.
● Operating result amounted to -10,093 (-11,408) TSEK.
● Earnings per share* amounted to -0.29 (-0.33) SEK .
● Cash and bank amounted to 30,393 (77,617) TSEK.
● Solidity** amounted to 79.2 (89,3)
First half year (2023-09-01 until 2024-02-29)
● Operating Income amounted to 7,099 (5,746) TSEK, of which
Cellaviva amounted to 6,580 (4,244) TSEK.
● Net Income amounted to 6,580 (4,244) TSEK.
● Operating result amounted to -19,889 (-20,327) TSEK.
● Earnings per share* amounted to -0.58 (-0.59) SEK .
Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the second quarter 2023/2024: 34,379,523 (34,379,523) shares. Number of shares in NextCell as of February 29, 2024: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.
Significant events in the second quarter
● At the end of January, NextCell published an update on the ongoing clinical trials. The largest ongoing study - ProTrans Young, which includes 66 patients - is progressing well.
● At the end of February,
Significant events after the reporting period
● NextCell announced in early March that it was establishing the subsidiary QVance to meet a Nordic demand for quality analyses. The launch is a strategic addition to NextCell to increase the company's sales and presence in the market for advanced therapy drugs.
● At the end of March, the company announced that the
● In mid-April,
● NextCell announced in mid-April that the Health and Social Care Inspectorate (IVO) has granted their tissue facility Cellaviva permission to handle the amniotic tissue.
● On
● On
This disclosure contains information that
For more information about
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com
Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma
For more information about Cellaviva, please contact
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se
Instagram: https://www,instagram.com/cellaviva
Certified Adviser
About
NextCell is a cell therapy company that is in phase 2 studies with the drug candidate
https://news.cision.com/nextcell-pharma-ab/r/nextcell-publishes-its-interim-report-2-2023-2024,c3967224
https://mb.cision.com/Main/15834/3967224/2758040.pdf
https://mb.cision.com/Public/15834/3967224/a12e215d71636fc1.pdf
(c) 2024 Cision. All rights reserved., source